NCT06282575 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06282575
Title	Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Jazz Pharmaceuticals
Indications	cholangiocarcinoma intrahepatic cholangiocarcinoma biliary tract cancer gallbladder cancer
Therapies	Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + Zanidatamab Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + Zanidatamab Cisplatin + Gemcitabine + Zanidatamab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SWE \| ROU \| ITA \| ISR \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| ARG

No variant requirements are available.